Cuban science present at the most important global event on Alzheimer's and Parkinson's

The clinical results of the neuroprotective drug NeuralCIM® (trade name of the NeuroEPO molecule) in neurodegenerative diseases, in Cuba; were exposed in recent days to the international scientific community, in the most important event on the subject that takes place in the world: the International Conference on Alzheimer's and Parkinson's disease (ADPD 2023), which was held in Sweden from March 28 to March 1. of April.

The Cuban researcher Leslie Pérez Ruiz, clinical promoter of the trials with NeuralCIM®, which evaluates the efficacy and safety of this product developed by the Center for Molecular Immunology (CIM), presented the findings of the clinical trials carried out in Cuba with this drug, in patients with mild or moderate Alzheimer's, and other neurodegenerative diseases.

According to the CIM, NeuralCIM® has been shown to improve memory, language and cognitive functions in patients, as well as reduce the adverse effects associated with other drugs. Clinical results with a good safety profile in patients with spinocerebellar ataxia, Parkinson's disease, and mild to moderate clinical Alzheimer's syndrome are encouraging.

The International Conference on Alzheimer's is an event that brings together leaders of the medical and scientific community linked to neurodegenerative diseases. Its objective is to share the advances and challenges in the research, prevention and treatment of Alzheimer's and other dementias.

This event had more than 4,000 participants, from 62 countries, mostly from the United States and Europe. By representing Cuba in this important scenario of world leaders in neurodegenerative diseases, it recognizes the value of science made in the Caribbean nation.

Currently, and for the first time in the field of dementia in Cuba, it is developing a clinical trial with an advanced level of precision focused on Alzheimer's disease.

This is the phase III clinical trial to evaluate the efficacy and safety of NeuralCIM® in patients with mild or moderate Alzheimer's.


The study consists of two investigations: one will be developed in Havana under the title "Evaluation of the efficacy and safety of the administration of NeuralCIM®/NeuralCIM®-Donepezil vs. Donepezil in patients with mild-moderate Alzheimer's disease”; and the other, to be carried out in the rest of the country, focuses on the "Evaluation of the effectiveness and safety of the nasal administration of NeuralCIM in patients with mild-moderate amnestic variant Alzheimer's disease phenotype."

Donepezil is the drug approved by the United States Food and Drug Administration (FDA) for international use in Alzheimer's dementia.

The first of the studies, in the capital, will reach a sample of 413 people, while the research in the rest of the national territory includes 1,456 patients.

According to Pérez Ruiz, in the arm of the study to be carried out in Havana, the patients will be diagnosed not only from a clinical point of view, but also from a molecular one, as required by good clinical practices in the world and by different agencies. regulations, for the accurate diagnosis of Alzheimer's. In the rest of the country, this diagnosis will be made from a clinical point of view since all the necessary technological equipment for molecular tests is not available.

Tomado de Cubadebate

RSS Minrex